What Causes Tigecycline Resistance and Why Alternatives Matter
Tigecycline, a glycylcycline antibiotic, targets multidrug-resistant Gram-negative bacteria like Acinetobacter baumannii and Klebsiella pneumoniae via protein synthesis inhibition. Resistance arises mainly from efflux pumps (e.g., Tet(X) enzymes or AdeABC systems) that expel the drug, ribosomal mutations, or plasmid-mediated mechanisms, reducing its efficacy in infections like ventilator-associated pneumonia or complicated intra-abdominal infections.[1][2]
Which Bacteria Commonly Show Tigecycline Resistance
Resistance is prevalent in:
- Carbapenem-resistant Acinetobacter baumannii (CRAB), with rates up to 50% in some ICUs.
- Extensively drug-resistant (XDR) Pseudomonas aeruginosa.
- Enterobacterales producing NDM or KPC enzymes, though less common than in CRAB.[3]
First-Line Alternatives for Tigecycline-Resistant Infections
For CRAB and similar pathogens, guidelines from IDSA and ESCMID recommend:
- Polymyxins (colistin or polymyxin B): IV or inhaled for pneumonia; high lung penetration but nephrotoxic. Often combined with others due to emerging resistance.
- Eravacycline: A newer tetracycine with better potency against efflux-mediated tigecycline resistance; FDA-approved for intra-abdominal infections.
- Omadacycline: Oral/IV option active against some resistant Gram-negatives, though data is limited for CRAB.[4][5]
| Alternative | Spectrum vs. Tigecycline-Resistant Pathogens | Key Limitations |
|-------------|---------------------------------------------|-----------------|
| Colistin | Strong vs. CRAB, XDR Enterobacterales | Kidney toxicity, resistance rising |
| Eravacycline | Retains activity via structural tweaks | IV-only, high cost |
| Omadacycline | Good for skin/soft tissue, some Gram-neg | Less data on CRAB |
Newer Agents and Combinations Tackling Resistance
- Cefiderocol: Siderophore cephalosporin that evades efflux pumps; approved for CRAB and resistant Pseudomonas. Trials show 60-70% success in tigecycline failures.[6]
- Meropenem-vaborbactam or imipenem-relebactam: Beta-lactamase inhibitors effective against KPC producers, sometimes outperforming tigecycline.
- Combinations like colistin + meropenem or fosfomycin boost efficacy; high-dose ampicillin-sulbactam works for some CRAB strains.[7]
How Do These Compare to Tigecycline in Practice
Eravacycline and cefiderocol match or exceed tigecycline's MICs against resistant isolates (e.g., eravacycline MIC90 2 mg/L vs. tigecycline's 8+ mg/L for CRAB). Survival rates in trials: cefiderocol ~65% vs. best available therapy ~50% for Acinetobacter pneumonia.[8] No direct head-to-head RCTs exist.
What If Resistance Involves Biofilms or Pneumonia
In biofilms (common in CRAB ventilator infections), inhaled colistin + IV cefiderocol penetrates better than tigecycline. Phage therapy or bacteriophage cocktails show promise in compassionate use cases but lack large trials.[9]
Emerging Options and Research Pipeline